share_log

10-K/A: Annual report (Amendment)

10-K/A: Annual report (Amendment)

10-K/A：年度報表(修正版)
美股sec公告 ·  04/30 05:29
牛牛AI助理已提取核心訊息
TC BioPharm, a biotechnology company, has filed its annual report for the fiscal year ended December 31, 2023. The report details the company's financial performance, business development, and future plans. Financially, TC BioPharm has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share figures in the provided text. However, the company's aggregate market value of shares held by non-affiliates was approximately $3.1 million as of June 30, 2023. As of March 29, 2024, 63,902,641 ordinary shares were outstanding. The company underwent an ADS ratio change on December 15, 2023, adjusting from one ADS representing one ordinary share to one ADS representing 20 ordinary shares. In terms of business development, the company's executive team is outlined, with details on their backgrounds and experience. The...Show More
TC BioPharm, a biotechnology company, has filed its annual report for the fiscal year ended December 31, 2023. The report details the company's financial performance, business development, and future plans. Financially, TC BioPharm has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share figures in the provided text. However, the company's aggregate market value of shares held by non-affiliates was approximately $3.1 million as of June 30, 2023. As of March 29, 2024, 63,902,641 ordinary shares were outstanding. The company underwent an ADS ratio change on December 15, 2023, adjusting from one ADS representing one ordinary share to one ADS representing 20 ordinary shares. In terms of business development, the company's executive team is outlined, with details on their backgrounds and experience. The report also mentions the company's compliance with SEC regulations and the adoption of an insider trading policy. Looking ahead, TC BioPharm has adopted a Clawback Policy effective December 1, 2023, and has outlined its equity compensation plans, including the granting of options to issue 42,395 ADSs. The company's future plans include continuing to develop its business and potentially expanding its market presence.
生物技術公司TC Biopharm已經提交了截至2023年12月31日的財政年度的年度報告。該報告詳細介紹了公司的財務業績、業務發展和未來計劃。財務方面，TC Biopharm沒有在提供的文本中披露具體的收入、營業利潤、淨利潤或攤薄後的每股收益數據。但是，截至2023年6月30日，該公司非關聯公司持有的股票的總市值約爲310萬美元。截至2024年3月29日，共有63,902,641股普通股已流通。該公司於2023年12月15日進行了ADS比率變動，從代表一股普通股的ADS調整爲代表20股普通股的ADS。在業務發展方面，概述了公司的執行團隊，並詳細介紹了他們的背景和經驗。該報告還提到了該公司遵守...展開全部
生物技術公司TC Biopharm已經提交了截至2023年12月31日的財政年度的年度報告。該報告詳細介紹了公司的財務業績、業務發展和未來計劃。財務方面，TC Biopharm沒有在提供的文本中披露具體的收入、營業利潤、淨利潤或攤薄後的每股收益數據。但是，截至2023年6月30日，該公司非關聯公司持有的股票的總市值約爲310萬美元。截至2024年3月29日，共有63,902,641股普通股已流通。該公司於2023年12月15日進行了ADS比率變動，從代表一股普通股的ADS調整爲代表20股普通股的ADS。在業務發展方面，概述了公司的執行團隊，並詳細介紹了他們的背景和經驗。該報告還提到了該公司遵守美國證券交易委員會法規的情況，並採用了內幕交易政策。展望未來，TC BioPharm已通過自2023年12月1日起生效的回扣政策，並概述了其股權補償計劃，包括授予發行42,395份美國存託證券的期權。該公司的未來計劃包括繼續發展其業務，並可能擴大其市場份額。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。